Brigatinib Approval Validates Ariad Buy, But Can Takeda Carve A Position?
The US approval of the targeted kinase inhibitor brigatinib seems to provide early validation of Takeda's recent acquisition of Ariad, but can the molecule carve its own niche amid intensifying same-class competition?
